Jazz Pharmaceuticals (JAZZ) CFO Matthew P. Young Sells 700 Shares of Stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $156.01, for a total value of $109,207.00. Following the sale, the chief financial officer now directly owns 38,465 shares of the company’s stock, valued at $6,000,924.65. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of JAZZ traded up $0.41 during trading hours on Thursday, hitting $158.45. 50,213 shares of the company were exchanged, compared to its average volume of 433,245. The firm has a market cap of $9,424.42, a P/E ratio of 16.53, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $163.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.15 and a current ratio of 3.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million for the quarter, compared to analyst estimates of $440.91 million. Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. research analysts predict that Jazz Pharmaceuticals will post 11.48 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in JAZZ. Dimensional Fund Advisors LP boosted its stake in Jazz Pharmaceuticals by 7.5% in the third quarter. Dimensional Fund Advisors LP now owns 247,170 shares of the specialty pharmaceutical company’s stock valued at $36,151,000 after buying an additional 17,272 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Jazz Pharmaceuticals by 77.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,889 shares of the specialty pharmaceutical company’s stock valued at $1,154,000 after purchasing an additional 3,437 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Jazz Pharmaceuticals by 795.4% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock valued at $255,000 after purchasing an additional 1,551 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of Jazz Pharmaceuticals by 29.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock valued at $257,000 after purchasing an additional 400 shares during the period. Finally, California Public Employees Retirement System raised its stake in shares of Jazz Pharmaceuticals by 4.8% during the 3rd quarter. California Public Employees Retirement System now owns 122,201 shares of the specialty pharmaceutical company’s stock valued at $17,872,000 after purchasing an additional 5,601 shares during the period. 91.21% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have weighed in on JAZZ. Piper Jaffray reissued a “buy” rating and set a $201.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. HC Wainwright reiterated a “neutral” rating and set a $160.00 price objective (up previously from $150.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 23rd. B. Riley restated a “buy” rating and issued a $206.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 20th. Seaport Global Securities set a $175.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 6th. Finally, Deutsche Bank set a $170.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, January 16th. Six equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $180.78.

ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals (JAZZ) CFO Matthew P. Young Sells 700 Shares of Stock” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/19/jazz-pharmaceuticals-jazz-cfo-matthew-p-young-sells-700-shares-of-stock.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply